Fourth-Generation Anti-CD19 CAR-T with IL-7/CCL19 Enhancement

The IL-7/CCL19-enhanced CAR-T cells targeting CD19 are a fourth-generation CAR-T cell therapy optimized for hematological malignancies. Based on the proven efficacy of CD19-targeted CAR-T therapy, this treatment integrates immune-supportive cytokines to enhance persistence, trafficking, and immune coordination.

CD19: A Well-Validated Target

CD19 is a well-validated surface antigen expressed across B-cell malignancies, including B-cell lymphomas and leukemias. Targeting CD19 enables highly specific and effective elimination of malignant B cells while maintaining a predictable safety profile.

Dual Armoring with IL-7 and CCL19

IL-7 supports CAR-T cell expansion, survival, and maintenance of a memory-like phenotype, contributing to long-term disease control. CCL19 is a chemokine that recruits endogenous T cells and dendritic cells, enhancing immune cell cooperation and promoting sustained antitumor immunity.

The combined expression of IL-7 and CCL19 helps recreate a lymphoid-like immune microenvironment, improving CAR-T cell functionality and persistence.

Therapeutic Principles

The therapeutic principles of IL-7/CCL19-enhanced anti-CD19 CAR-T cells are designed to maximize efficacy, persistence, and coordinated immune response in hematologic malignancies:

• Targeted B-Cell Elimination: CAR-T cells specifically recognize and destroy CD19-expressing malignant B cells, including in relapsed or refractory cases.
• Enhanced CAR-T Expansion and Persistence: IL-7 promotes T-cell survival, expansion, and memory phenotype maintenance, ensuring long-term antitumor activity.
• Immune Recruitment and Coordination: CCL19 attracts endogenous T cells and dendritic cells to the tumor microenvironment, enhancing immune system synergy and sustained antitumor responses.
• Overcoming Therapy Resistance: The combined cytokine armoring improves CAR-T functionality in patients who have failed multiple lines of chemotherapy or monoclonal antibody therapy.

Key Advantages

• Clinically validated CD19 targeting for highly specific B-cell malignancy therapy.
• Enhanced CAR-T survival and expansion through IL-7-mediated memory cell support.
• Improved immune coordination via CCL19-mediated recruitment of endogenous immune cells.
• Sustained antitumor activity reducing relapse risk in refractory cases.
• Optimized for hematologic malignancies, leveraging fourth-generation CAR-T design for superior efficacy.

Clinical Evidence

Clinical data reported in Cell Discovery (2024;10:5) demonstrate encouraging efficacy of IL-7/CCL19-enhanced CD19-specific CAR-T therapy in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL, a common type of non-Hodgkin lymphoma). Among 39 evaluable patients, the complete response (CR) rate reached 56.41%, with an overall response rate (ORR) of 79.49%. With a median follow-up of 32 months, the median progression-free survival (mPFS) was 13 months, and median overall survival (OS) was not reached. These long-term follow-up data suggest that the CAR-T cells can induce durable responses with a median overall survival of greater than 2 years, and have a manageable safety profile in patients with R/R LBCL.

Potential Therapeutic Indications

CD19 is a lineage-defining surface antigen consistently expressed across B-cell malignancies. The table below summarizes representative CD19-positive cancers that constitute the primary therapeutic indications for fourth-generation CAR-T therapy enhanced with IL-7 and CCL19.

• IL-7 CCL19-Enhanced CD19 CAR-T for B-Cell Lymphoma